About bioblast pharma ltd - ENLV
Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
ENLV At a Glance
Enlivex Ltd.
14 Einstein Street
Ness Ziona, Tel Aviv 7403618
| Phone | 972-8-662-3301 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | 1.24B | |
| Sector | Health Technology | Employees | 34 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ENLV Valuation
| P/E Current | 0.003 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 0.028 |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.086 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.969 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.022 |
ENLV Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | 36,339,058.824 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ENLV Liquidity
| Current Ratio | 193.236 |
| Quick Ratio | 193.236 |
| Cash Ratio | 0.65 |
ENLV Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | 104.942 |
| Return on Equity | 126.168 |
| Return on Total Capital | 63.832 |
| Return on Invested Capital | 126.125 |
ENLV Capital Structure
| Total Debt to Total Equity | 0.033 |
| Total Debt to Total Capital | 0.033 |
| Total Debt to Total Assets | 0.028 |
| Long-Term Debt to Equity | 0.02 |
| Long-Term Debt to Total Capital | 0.02 |